Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06624670
Registration number
NCT06624670
Ethics application status
Date submitted
30/09/2024
Date registered
3/10/2024
Date last updated
9/07/2025
Titles & IDs
Public title
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Query!
Scientific title
A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy
Query!
Secondary ID [1]
0
0
2024-514306-31-00
Query!
Secondary ID [2]
0
0
1368-0140
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pyoderma Gangrenosum
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Spesolimab
Treatment: Drugs - Placebo matching to spesolimab
Treatment: Drugs - Prednisone
Treatment: Drugs - Prednisolone
Experimental: Spesolimab -
Placebo comparator: Placebo -
Treatment: Drugs: Spesolimab
Solution for infusion
Treatment: Drugs: Placebo matching to spesolimab
Placebo matching to spesolimab
Treatment: Drugs: Prednisone
Prednisone
Treatment: Drugs: Prednisolone
Prednisolone
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Achievement of complete closure (PGAR-100 (100% pyoderma gangrenosum area reduction)) of the target PG ulcer at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later)
Query!
Assessment method [1]
0
0
PGAR-100 is defined as complete closure and re-epithelisation of a PG ulcer without drainage and requirements for dressing.
Query!
Timepoint [1]
0
0
Up to Week 28.
Query!
Secondary outcome [1]
0
0
Key secondary endpoint: Achievement of PGAR-100 of the target PG ulcer at Week 26 confirmed at the next consecutive visit (at least 2 weeks later)
Query!
Assessment method [1]
0
0
PGAR-100 is defined as complete closure and re-epithelisation of a PG ulcer without drainage and requirements for dressing.
Query!
Timepoint [1]
0
0
Up to Week 28.
Query!
Secondary outcome [2]
0
0
Achievement of 50% area reduction (PGAR-50) of the target PG ulcer at any time up to Week 26
Query!
Assessment method [2]
0
0
Achievement of a PGAR-50 defines an area reduction of a PG ulcer from baseline by 50%.
Query!
Timepoint [2]
0
0
Up to Week 26.
Query!
Secondary outcome [3]
0
0
Achievement of = 3 point reduction in NRS Pain score from baseline at Week 26
Query!
Assessment method [3]
0
0
Numeric Rating Scale for Pain (NRS Pain) is a unidimensional measure of pain intensity. It is a 11-point numeric scale, in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain, with 0 representing "no pain" and 10 representing "worst pain imaginable". Trial participant is asked to report their pain intensity in the last 24 h.
Query!
Timepoint [3]
0
0
At baseline and at Week 26.
Query!
Secondary outcome [4]
0
0
Achievement of a DLQI of = 5 at Week 26
Query!
Assessment method [4]
0
0
Dermatology Life Quality Index (DLQI) is a trial participant-administered, quality of life questionnaire consisting of 10 questions that cover 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, problems with treatment). Response categories include "not relevant" or "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3). Question 7 is a "yes"/ "no" question where "yes" is scored as 3. DLQI total score is calculated by summing the scores of each question, resulting in a range of 0 to 30, with higher scores indicating more impairment of a trial participant's quality of life.
Query!
Timepoint [4]
0
0
At Week 26.
Query!
Secondary outcome [5]
0
0
Achievement of PGAR-100 of any measurable PG ulcer (=5 cm^2 at baseline) at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later)
Query!
Assessment method [5]
0
0
PGAR-100 is defined as complete closure and re-epithelisation of a PG ulcer without drainage and requirements for dressing.
Query!
Timepoint [5]
0
0
Up to Week 28.
Query!
Secondary outcome [6]
0
0
Achievement of PGAR-100 of all measurable PG ulcers (=5 cm^2 at baseline) at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later)
Query!
Assessment method [6]
0
0
PGAR-100 is defined as complete closure and re-epithelisation of a PG ulcer without drainage and requirements for dressing.
Query!
Timepoint [6]
0
0
Up to Week 28.
Query!
Secondary outcome [7]
0
0
Time to recurrence among trial participants who had achieved complete response (CR, complete closure of all PG ulcers) at Week 26 up to Week 52
Query!
Assessment method [7]
0
0
Recurrence is defined as emergence of the disease (PG ulcer\[s\]) at the previous ulcer sites(s) or emergence of any new PG ulcer(s).
Query!
Timepoint [7]
0
0
Up to Week 52.
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
1. Adult trial participants, aged =18 years (if local legislation for age of consent differs, then local legislation will be followed) at screening.
2. Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
3. A confirmed diagnosis of ulcerative pyoderma gangrenosum (PG) (=10 points on the PARACELSUS score) that requires systemic therapy in the opinion of the investigator. The diagnosis needs to be confirmed by an Adjudication Committee. Trial participants with mixed PG subtypes are eligible as long as the target lesion is of the ulcerative subtype.
4. At least one measurable (defined as measuring =5 cm^2) PG ulcer. In trial participants with more than one PG ulcer, the target PG ulcer will be selected by the investigator and confirmed by external Adjudication Committee.
5. At the time of the Screening Visit, a maximum duration of 6 months since the target ulcer in the current PG episode was diagnosed. Target ulcers >6 months since diagnosis are allowed if they are active and progressing, as judged by the investigator and confirmed by an Adjudication Committee.
6. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information and in the protocol.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
1. Trial participants with non-PG lesions.
2. Trial participants with a target PG ulcer measuring >80 cm^2.
3. Trial participants with chronic, non-inflamed PG wounds or ulcers that are not responsive to immunosuppressive therapy, as determined by an Adjudication Committee.
4. Presence of active ulcer infection at the Screening Visit (unless treated and resolved prior to administration of the first dose of trial medication) based on investigator assessment.
5. Presence of persistent or recurring bacterial infection requiring systemic antibiotic therapy; or clinically significant viral, fungal, or parasitic infections within 2 weeks prior to the Screening Visit. Any such infection must be resolved, with treatment completed =2 weeks prior to the Screening Visit. No new/recurrent infections should have occurred prior to Visit 2.
6. "Active or latent tuberculosis (TB)
* Participants with active TB are excluded
* Participants with latent TB may be included if treatment of latent TB, as per local guidelines, is initiated prior to randomization and completed during the course of the trial."
7. Chronic or acute infections including Human immunodeficiency virus (HIV) infections and viral hepatitis (including occult hepatitis); the corresponding laboratory tests will be performed during screening. A trial participant can be re-screened if the trial participant was treated and is cured from the acute infection.
8. Severe, progressive, or uncontrolled hepatic disease, defined as >3x Upper Limit of Normal (ULN) elevation in Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) or alkaline phosphatase, or >2x ULN elevation in total bilirubin.
Further exclusion criteria apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/02/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
5/10/2027
Query!
Actual
Query!
Sample size
Target
90
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Skin and Cancer Foundation - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Royal North Shore Hospital-St Leonards-20807 - St Leonards
Query!
Recruitment hospital [3]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Hampshire
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Dakota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Utah
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Caba
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Rosario
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Graz
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Salzburg
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Leuven
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Brasilia
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Porto Alegre
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Santo André
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Alberta
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Quebec
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Beijing
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Changchun
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Changsha
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Chengdu
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Hangzhou
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Jinan
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Shanghai
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Shenzhen
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Wuhan
Query!
Country [36]
0
0
Finland
Query!
State/province [36]
0
0
Helsinki
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Antony
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Nice Cedex 3
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Paris
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Berlin
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Erlangen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Essen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Freiburg
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Würzburg
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Milano
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Pisa
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Roma
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Rozzano (MI)
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Torino
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Aichi, Toyoake
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Hokkaido, Sapporo
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Hyogo, Nishinomiya
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Mie, Tsu
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Miyagi, Sendai
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Tochigi, Shimotsuke
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Tokyo, Itabashi-ku
Query!
Country [57]
0
0
Malaysia
Query!
State/province [57]
0
0
Ipoh
Query!
Country [58]
0
0
Malaysia
Query!
State/province [58]
0
0
Kuching
Query!
Country [59]
0
0
Malaysia
Query!
State/province [59]
0
0
Pulau Pinang
Query!
Country [60]
0
0
Norway
Query!
State/province [60]
0
0
Oslo
Query!
Country [61]
0
0
Norway
Query!
State/province [61]
0
0
Stavanger
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Warsaw
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Wroclaw
Query!
Country [64]
0
0
Portugal
Query!
State/province [64]
0
0
Coimbra
Query!
Country [65]
0
0
Portugal
Query!
State/province [65]
0
0
Lisboa
Query!
Country [66]
0
0
Portugal
Query!
State/province [66]
0
0
Porto
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Madrid
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Malaga
Query!
Country [69]
0
0
Sweden
Query!
State/province [69]
0
0
Stockholm
Query!
Country [70]
0
0
Switzerland
Query!
State/province [70]
0
0
Zürich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1 ulcer that measures between 5 cm\^2 to 80 cm\^2 in size. This study has 2 parts. In Part 1, participants are put into groups randomly, which means by chance. 1 group gets spesolimab and the other group gets placebo. Placebo injections look like spesolimab injections, but do not contain any medicine. Every participant has a 2 in 3 chance of getting spesolimab. For the first 8 weeks, participants also take corticosteroid medicine by mouth. In Part 2, participants are put into groups again. Participants without open ulcers have an equal chance of getting spesolimab or placebo. Participants with open skin ulcers will get spesolimab. In both parts, participants receive spesolimab or placebo as an infusion into a vein every 4 weeks. Participants are in the study for about 1.5 years. During this time, they visit the study site 20 times. At study visits, doctors check the participant's skin for signs of PG. The doctors also regularly check participants' health and take note of any unwanted effects. The results of the groups are compared to see whether the treatment works.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06624670
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-800-243-0127
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06624670
Download to PDF